Use of Sleep Endoscopy to Predict Outcomes of Pediatric Adenotonsillectomy

NCT ID: NCT02693977

Last Updated: 2023-08-22

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 347 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-02-01
• Study Completion Date: 2023-03-31

Brief Summary

Pediatric obstructive sleep apnea (OSA) is associated with heavy snoring and brief pauses in breathing during sleep. It affects at least 1-3% of the general pediatric population with greater prevalence among certain high risk groups such as children with obesity, Down syndrome, craniofacial anomalies, or neuromuscular disorders. Several studies have shown that, even after having adenotonsillectomy (AT), approximately 30% of children continue to struggle with OSA. They further found that older children (age > 7 yrs), obesity, and high pre-operative OSA severity were all risk factors contributing to residual OSA. Despite these known risk factors, the ability to predict each individual patient's risk of residual OSA after tonsil surgery is difficult. Determining what tool will best predict residual OSA is an important step towards more effective post-surgery OSA management.

The purpose of this study is to determine whether sleep endoscopy can predict whether their AT will be successful as a treatment for OSA. Our hypothesis is that subjects with multiple areas of obstruction in addition to large tonsils will be more likely to have residual OSA after AT. Sleep endoscopy is a procedure performed during drug-induced sleep that involves passing a flexible endoscope through the subject's nose into the back of the throat to look for sources of obstruction while breathing spontaneously.

This will be a prospective cohort study examining subjects between the ages of 2 and 18 who are having AT for treatment of obstructive sleep apnea (OSA) and are considered high risk for residual OSA after surgery. High risk will be defined based on the following criteria: obesity, Down syndrome, African American race, severe baseline OSA, and age > 7 yrs. Eligible subjects will be recruited from the pediatric otolaryngology clinic at the time of initial evaluation for AT. Subjects will undergo a sleep endoscopy under moderate sedation at the time of AT. All patients will be asked to complete a preoperative sleep study to confirm the diagnosis of OSA and a postoperative sleep study to determine the impact of AT and the presence of residual OSA. Secondary outcome measures will include several questionnaires assessing generic and OSA-specific quality of life as well as subjective measures of cognitive/executive functioning and daytime sleepiness.

Detailed Description

The purpose of this study is to determine whether sleep endoscopy performed in high-risk pediatric patients with obstructive sleep apnea (OSA) at the time of adenotonsillectomy (AT) can predict whether the AT will be successful as an initial treatment for OSA. We hypothesize that patients with multiple sites of obstruction in addition to adenotonsillar hypertrophy (e.g. the nasal airway, velum, base of tongue, supraglottis) will be more likely to have residual sleep apnea on postoperative sleep testing.

Obstructive sleep apnea syndrome OSAS is defined as the symptomatic repetitive obstruction of the upper airway during sleep and has been estimated to affect 1-6% of the general pediatric population. Untreated OSAS in children has been associated with childhood hypertension, autonomic dysfunction, attention deficit/hyperactivity disorder, neurobehavioral impairment, and poor quality of life. These sequelae contribute to a 226% increase in health care utilization among children with OSAS compared to controls, primarily in the form of increased hospitalizations, emergency department visits, and medication use. Adenotonsillar hypertrophy is considered the most common risk factor for OSAS in children, therefore unlike in adult OSAS, adenotonsillectomy (AT) is the recommended first line treatment. In large part due to the increasing awareness and diagnosis of pediatric OSAS, the incidence of AT increased dramatically from 1980 to 2005. With more than 500,000 procedures performed per year, AT is now the second-most common procedure performed in children in the US, and 77% of these have OSAS as the primary indication.

Current guidelines recommend AT as a first line treatment for pediatric OSAS even for those patients who may have significant risk of post-AT OSAS. Estimates of the prevalence of persistent OSAS after AT vary widely due to use of different polysomnographic criteria for diagnosis. Studies that assessed the risk of post-AT OSAS using a conservative adult threshold for diagnosis demonstrated that even with this high threshold at least 13-29% of children undergoing AT for pediatric OSAS will have significant residual disease and approximately 75% of children will fail to achieve normalization on polysomnography. Specific populations of patients that have been recognized to be particularly at risk for post-AT OSAS include those with severe baseline OSAS, Down syndrome, obesity, and age > 7 years. In obese patients, the prevalence of post-AT OSAS has been reported as high as 73-88%. Since obesity has tripled over the last three decades and now affects approximately 8% of children aged 2-5 years, 18% of children aged 6-11 and 21% of adolescents aged 12-19 years, the problem of persistent OSAS after AT is likely to continue to grow.

Even within populations at risk for AT failure, there is a wide variation in treatment response. One study of morbidly obese children undergoing AT demonstrated only a 37% cure rate while 53% had sufficient residual OSAS to require further treatment with continuous positive airway pressure (CPAP). However, no significant baseline differences were identified between surgical responders and non-responders. The mechanism for failure in this population is unclear, but it is presumed that increased generalized adiposity leads to multilevel obstruction similar to obese adults, thus decreasing the likelihood of success with AT. Similarly a poor but still variable response to AT was observed in children with Down syndrome with post-AT success varying between 18% and 55% depending on the specific criteria used. There are no studies that have clearly identified predictors of AT outcome within the Down syndrome population, however, some studies of Down syndrome patients who failed AT have suggested that multilevel obstruction is common. Thus, although specific populations of patients are known to have greater risk of post-AT OSAS on average, the individual characteristics causing persistent disease remain unclear. Accurate prognostication of the risk of residual OSA after AT for any individual patient remains a challenge. Studies of patients with persistent post-AT OSAS have suggested that multilevel obstruction at locations besides the tonsils or adenoids are likely contributors, but this has not been clearly demonstrated. In this study, we present a novel concept for building a composite model to predict the outcome of AT in children with OSAS. This model will include not just baseline features of history and physical exam but also the findings of dynamic sleep-related collapse at specific anatomic sites in the pharynx observed during sleep endoscopy. This model will give further insight into the mechanisms of airway obstruction as well as the possible reasons for persistent OSAS after AT.

A rating scale for DISE has previously been described in an attempt to standardize the reporting of endoscopic findings in adults with OSAS. This rating scale evaluates the degree and pattern of obstruction at four levels of the pharynx: the Velum (soft palate), Oropharynx (including the tonsils), Tongue base, and Epiglottis (VOTE). The VOTE rating scale has been demonstrated to have moderate to substantial inter-rater reliability with kappa values ranging from 0.4-0.8 depending on the specific structures being compared. Other investigators have utilized modified versions of the VOTE rating scale in children, including other levels of the airway such as the nasal airway, nasopharynx, and supraglottis. One recent study demonstrated that sleep endoscopy findings in children were more reliable than during awake endoscopy and noted a strong correlation between polysomnography results and the overall impression of OSA severity during endoscopy.

Dexmedetomidine, which will be used in this study, is a highly selective α2-adrenoceptor agonist that has been demonstrated to result in a sedated sleep similar to natural sleep without causing respiratory depression. Though there have been some reports of transient bradycardia and blood pressure changes in response to dexmedetomidine infusion (usually transient hypotension of 10% with slow infusion) these cardiovascular effects are mitigated by co-administration of a bolus of ketamine. These patients would already have been using dexmedetomidine or a different anesthesia for their tonsil surgery. The dexmedetomidine is not an intervention or part of this study.

In a preliminary retrospective review of our patient population and surgical volume, we examined the electronic medical record of all patients who underwent AT over a 12 month period. 498 patients were identified, operated on by the four pediatric otolaryngologists in the group. Approximately 200 (40%) of these were performed for OSAS in patients that could be considered high risk for residual post-AT OSAS and would meet inclusion/exclusion criteria described below.

Untreated OSA in children has been associated with childhood hypertension, autonomic dysfunction, attention-deficit/hyperactivity disorder, poor school performance, and poor quality of life. These sequelae contribute to a 226% increase in health care utilization among children with OSA compared to controls. Residual OSA after AT in the pediatric population remains a serious concern; as the patient grows and changes, their airway physiology also changes. Although there is a growing body of research suggesting demographic and comorbidity risk factors for post-AT residual OSA, the ability to accurately predict the likelihood or severity of residual OSA for any given individual remains elusive. Possible tools for the evaluation of post-AT OSA in pediatric populations include radiologic examinations, cine MRI scanning, and endoscopic evaluation, along with polysomnography, validated questionnaires, and physical examinations. Determining what instruments best predict residual OSA after surgical intervention is an important step towards more effective OSA management.

Conditions

Obstructive Sleep Apnea

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Sleep Endoscopy

Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Obesity (BMI > 95th percentile or z-score > 1.96 for age)
• Down syndrome
• African American race
• Pre-operative AHI > 10
• Age > 7 years
• Tonsils rated 1+ but persistent symptoms of OSA

Exclusion Criteria

• Craniofacial anomalies (including cleft lip and palate, Pierre Robin sequence)
• Genetic abnormalities
• Neuromuscular disorders (including cerebral palsy, hypotonia)
• Subglottic or tracheal stenosis
• Tracheostomy dependence
• Severe cardiopulmonary disease requiring supplemental oxygen at night
• Primary caregiver(s) are unable to complete questionnaires in English or Spanish, cannot be reached by telephone, or are planning to move during the study period

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Oregon Health and Science University

OTHER

Sponsor Role: lead

Responsible Party

Derek Lam, MD, MPH

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Derek Lam, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Oregon Health and Science University

Locations

Doernbecher Children's Hospital

Portland, Oregon, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

1K23HL127132-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB00009825

Identifier Type: -

Identifier Source: org_study_id